| Ritchie, David |
C-SMART, NCT04534725: COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; |
|
|
| Completed | 3 | 441 | RoW | Interferon alfa, Selinexor, Lenzilumab | Peter MacCallum Cancer Centre, Australia | Cancer, Covid19, Respiratory Viral Infection | 11/22 | 04/23 | | |
ACTRN12619000581167: Brentuximab Vedotin in combination with donor lymphocyte infusions for Hodgkin lymphoma relapsing or persisting after allogeneic stem cell transplantation |
|
|
| Recruiting | 2 | 10 | | | Melbourne Health, Millenium Pharmaceuticals | Hodgkin lymphoma | | | | |
NIVALLO, NCT03146468: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 14 | RoW | Nivolumab Injection, Opdivo | Melbourne Health | Haematological Malignancy | 03/22 | 03/22 | | |
ACTRN12620001339943p: REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT)
Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia |
|
|
| Not yet recruiting | 1/2 | 20 | | | The Royal Melbourne Hospital, Maddie Riewoldt's Vision | One of the health conditions being studied in this trial will be Poor Graft Function
; One of the health conditions being studied in this trial will be Aplastic Anaemia | | | | |
ACTRN12620001339943: REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT)
Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia |
|
|
| Recruiting | 1/2 | 20 | | | The Royal Melbourne Hospital, Maddie Riewoldt's Vision | One of the health conditions being studied in this trial will be Poor Graft Function
, One of the health conditions being studied in this trial will be Aplastic Anaemia | | | | |
ACTRN12617000473369: A clinical trial to evaluate the safety of nivolumab for relapsed or residual haematological cancers after blood or bone marrow transplantation |
|
|
| Active, not recruiting | 1/2 | 14 | | | Melbourne Health, Bristol-Myers Squibb | Haematological malignancies | | | | |
RESELECT2, NCT06607367: REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 |
|
|
| Not yet recruiting | 1/2 | 20 | RoW | Ruxolitinib (JAKAVI®), Eltrombopag (Revolade®) | Melbourne Health | Poor Graft Function, Aplastic Anemia Idiopathic | 10/25 | 10/26 | | |
ACTRN12619000556145: Maintenance treatment with low-dose lenalidomide after allogeneic stem cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndrome |
|
|
| Recruiting | 1 | 20 | | | Melbourne Health, Celgene | Acute myeloid leukaemia
, Myelodysplastic syndrome | | | | |
ACTRN12622000308796: Short-course treatment with venetoclax prior to non-myeloablative conditioning allogeneic stem cell transplantation for patients with haematological malignancies. |
|
|
| Recruiting | 1 | 18 | | | Melbourne Health, The Commonwealth of Australia - Medical Research Future Fund (MRFF) | Acute leukaemia (myeloid and/or lymphoid, or biphenotypic), Myelodysplastic syndrome, Chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma, Plasma cell myeloma | | | | |
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 18 | RoW | Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide | Melbourne Health | Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma | 03/26 | 03/26 | | |
